{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-001237","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2023-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.703851+00:00","generated_at":"2026-06-20T16:01:18.728192+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Matinas BioPharma partners with Resilience to explore oral nucleic acid delivery via LNC platform","bullets":["Material Transfer and Evaluation Agreement with National Resilience for oral delivery of nucleic acids.","Research program includes design, formulation, optimization, and in vitro/in vivo testing of nucleic acids with LNC platform.","Collaboration is distinct from ongoing work with BioNTech, allowing simultaneous platform development.","No financial terms disclosed; partnership aims to demonstrate LNC platform capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-001237","json":"https://secwatch.observer/filing/0001493152-23-001237.json","markdown":"https://secwatch.observer/filing/0001493152-23-001237.md","text":"https://secwatch.observer/filing/0001493152-23-001237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223001237/0001493152-23-001237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223001237/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:01:18.728192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}